Compare ROIV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | CRDO |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 50.7B |
| IPO Year | 2021 | 2022 |
| Metric | ROIV | CRDO |
|---|---|---|
| Price | $34.02 | $268.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $28.94 | ★ $179.62 |
| AVG Volume (30 Days) | 5.3M | ★ 9.2M |
| Earning Date | 05-28-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 765.52 |
| EPS | N/A | ★ 2.51 |
| Revenue | $8,260,000.00 | ★ $1,335,116,000.00 |
| Revenue This Year | N/A | $210.92 |
| Revenue Next Year | $744.61 | $57.22 |
| P/E Ratio | ★ N/A | $108.37 |
| Revenue Growth | N/A | ★ 205.68 |
| 52 Week Low | $10.71 | $84.25 |
| 52 Week High | $32.80 | $308.67 |
| Indicator | ROIV | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 72.76 | 59.27 |
| Support Level | $26.65 | $132.85 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.17 | 25.37 |
| MACD | 0.41 | 2.02 |
| Stochastic Oscillator | 93.41 | 61.78 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.